New pharmacological approach for inflammatory bowel disease

Please use this identifier to cite or link to this item: http://hdl.handle.net/10400.21/12230

Title:	New pharmacological approach for inflammatory bowel disease
Author:	Silva, Inês Pinto, Rui Mateus, Vanessa
Keywords:	Inflammatory bowel disease Ulcerative colitis Crohn disease Erythropoietin Animal model IDI&CA_COLITIS/2019
Issue Date:	Sep-2019
Citation:	Silva IJ, Pinto R, Mateus V. New pharmacological approach for inflammatory bowel disease. In: 3rd World Congress on Pharmacology & Toxicology, Crowne Plaza London – Heathrow, West Drayton (UK), September 12-14, 2019.
Abstract:	Inflammatory bowel disease includes Crohn's disease and ulcerative colitis. Chronic inflammatory disease of the gastrointestinal (GI) tract is characterized by recurrent ulceration. IBD affects 7–10% of people worldwide, mainly of Caucasian descent. It manifests into several intestinal and extra-intestinal symptoms, mainly related to oxidative stress, inflammation, and autoimmune reaction. Aim of the study: evaluate the influence of a new pharmacological approach with erythropoietin in the establishment and development of inflammation associated with IBD, through of an experimental colitis model in rodents.
Description:	IDI&CA_COLITIS/2019
Peer review:	yes
URI:	http://hdl.handle.net/10400.21/12230
Appears in Collections:	ESTeSL - Comunicações

Files in This Item:

File	Description	Size	Format
New pharmacological approach for inflammatory bowel disease.pdf		1,85 MB	Adobe PDF	View/Open